Premium
The role of hematopoietic stem cell transplantation with relapsed or primary refractory childhood B‐cell non‐Hodgkin lymphoma and mature B‐cell leukemia: A retrospective analysis of enrolled cases in Japan
Author(s) -
Fujita Naoto,
Mori Tetsuya,
Mitsui Tetsuo,
Inada Hiroko,
Horibe Keizo,
Tsurusawa Masahito
Publication year - 2008
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.21585
Subject(s) - medicine , salvage therapy , hematopoietic stem cell transplantation , refractory (planetary science) , lymphoma , chemotherapy , transplantation , leukemia , disease , oncology , surgery , physics , astrobiology
Background There have been excellent treatment results for children with B‐cell non‐Hodgkin lymphoma (B‐NHL) and mature B‐cell leukemia (B‐ALL) in the last few decades. However, a small subset of relapsed or refractory patients, after first‐line therapy, still have a poor prognosis. Procedure Thirty‐three patients with relapsed or primary refractory B‐NHL/B‐ALL among 327 newly diagnosed patients between 1996 and 2004 were analyzed retrospectively. Results After salvage therapy, 18 patients were chemotherapy‐sensitive and 15 patients suffered from progression. Among 18 patients who had a chemotherapy‐sensitive disease, 4 of 5 patients who underwent hematopoietic stem cell transplantation (HSCT) during remission survived without progression, while 3 of 12 patients who did not receive HSCT were alive without disease progression. Fifteen patients never sensitive to salvage therapy died. Conclusions Patients with relapsed/primary refractory B‐NHL/B‐ALL have a poor prognosis with current treatment approaches, while the patients sensitive to salvage therapy have a respectable chance to achieve a sustained complete second remission with HSCT. Pediatr Blood Cancer 2008;51:188–192. © 2008 Wiley‐Liss, Inc.